La vendita allo scoperto per UroGen Pharma dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di UroGen Pharma. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

UroGen Pharma (NASDAQ:URGN) Azioni, Report sulle vendite allo scoperto

UroGen Pharma

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

UroGen Pharma Ltd

In the current session, the stock is trading at $78.70, after a 1.72% spike. Over the past month, Mueller Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLI#NYSE">MLI</a>) stock increased by 6.58%, and in the past year, by 38.92%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1748988022_0.png" alt="Past Year Chart" />

<h3>Mueller Industries P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Mueller Industries has a lower P/E than the aggregate P/E of 27.71 of the Machinery industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1748988022_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

News

Intraday Update

Markets

Price Over Earnings Overview: Mueller Industries

Analysts' ratings for Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $28.0, a high estimate of $30.00, and a low estimate of $26.00. This upward trend is apparent, with the current average reflecting a 3.7% increase from the previous average price target of $27.00.
<img src="https://www.benzinga.com/files/images/story/2025/1748988017_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Kinder Morgan. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selman Akyol</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$28.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Jeremy Tonet</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$28.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Brandon Bingham</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Kinder Morgan. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Kinder Morgan compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Kinder Morgan's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Kinder Morgan's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/KMI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Kinder Morgan analyst ratings.</a>
<h2>Get to Know Kinder Morgan Better</h2>
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 80,000 miles of gas, refined products, and carbon dioxide pipelines. The company also owns one of the largest portfolios of gas and refined products storage and terminals. Most of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
<h3>Kinder Morgan's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3M period, Kinder Morgan showcased positive performance, achieving a revenue growth rate of 10.39% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Energy sector.
Net Margin: Kinder Morgan's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.81%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Kinder Morgan's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.33%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Kinder Morgan's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.99%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 1.07, Kinder Morgan adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Demystifying Kinder Morgan: Insights From 4 Analyst Reviews

Quanta Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) has outperformed the market over the past 20 years by 11.93% on an annualized basis producing an average annual return of 20.26%. Currently, Quanta Services has a market capitalization of $52.85 billion. 
Buying $100 In PWR: If an investor had bought $100 of PWR stock 20 years ago, it would be worth $3,974.25 today based on a price of $356.49 for PWR at the time of writing.
<h3>Quanta Services's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748988016_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Quanta Services 20 Years Ago Would Be Worth Today

Offerings

Dorian LPG Files For Potential Mixed Shelf; Size Not Disclosed

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) has outperformed the market over the past 15 years by 9.69% on an annualized basis producing an average annual return of 21.89%. Currently, Regeneron Pharmaceuticals has a market capitalization of $52.77 billion. 
Buying $100 In REGN: If an investor had bought $100 of REGN stock 15 years ago, it would be worth $1,840.98 today based on a price of $488.79 for REGN at the time of writing.
<h3>Regeneron Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748987111_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

REGN

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Rumors

$BTC

Watching Trump Media & Technology Group; Traders Circulate President Trump's Truth Social Files For A Bitcoin ETF

<a href="https://x.com/seckennedy/status/1930012848056365294?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg">https://x.com/seckennedy/status/1930012848056365294?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg</a>

General

BNTX

MRNA

NVAX

US Health Secretary Kennedy Posts On X "I want to address those of you who have anxieties about @US_FDA's limited approval of a new mRNA COVID vaccine for high-risk populations. Moderna has agreed to a true placebo-controlled trial of the new vaccine....."

Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) has outperformed the market over the past 5 years by 2.2% on an annualized basis producing an average annual return of 15.22%. Currently, Devon Energy has a market capitalization of $20.54 billion. 
Buying $1000 In DVN: If an investor had bought $1000 of DVN stock 5 years ago, it would be worth $2,192.47 today based on a price of $31.92 for DVN at the time of writing.
<h3>Devon Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748986211_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Devon Energy Stock In The Last 5 Years

Recently disclosed clinical cohort data from high (1x1015&nbsp;total vg) and low dose (5.7x1014&nbsp;total vg) TSHA-102 from REVEAL adolescent/adult and pediatric Phase 1/2 trials
Caregiver research regarding gain/regain of developmental milestones supporting alignment with FDA on primary endpoint in the pivotal Part B trial of TSHA-102
Previously disclosed preclinical data supporting broad biodistribution across brain and spinal cord regions following lumbar intrathecal delivery of AAV9 gene therapy vectors in non-human primates
Symposium on Rett syndrome natural history data findings
DALLAS, June 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced details for three oral presentations reviewing recent updates supporting its TSHA-102 program in clinical evaluation for Rett syndrome, and a Taysha-hosted symposium on the Company's analysis of the natural history study data at the 2025 International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting, taking place in&nbsp;Boston from&nbsp;June 9-11, 2025. The three presentations will also be presented during a poster session on Monday, June 9, 2025, from 5:00-7:00 PM EST. Additional details on the meeting can be found at IRSF's <a href="https://www.globenewswire.com/Tracker?data=fRcesPdJZ6naTCRmA1KdBnqknjMPiqUOSAZbibyIduSLIZBHD1sKDusevNNC9IDpOhcz49wKMcjwGxoZlu3UJQq_yJHoYjp2wi2ObKNmW3dZm0YC9_b3FmpZWcqr8vQ-RiqQI0N_8TElkfU9BZ2OAajR6CbuQwJ7QUjVqGCV5og=">website</a>.

Biotech

TSHA

Taysha Gene Therapies To Present Clinical And Preclinical Data Supporting TSHA-102 Rett Syndrome Program, Including Dose Cohort Results, Caregiver Insights Aligning With FDA Endpoints, At IRSF Scientific Meeting June 9–11, 2025 In Boston

LUCD

Lucid Diagnostics Files For Offering Of 36M Shares Of Common Stock

Lumentum Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) shares are rising in extended trading on Tuesday after the company updated its guidance for the current quarter ahead of a <a href="https://www.benzinga.com/topic/bofa">scheduled presentation this week</a>.
What Happened: After the market close on Tuesday, Lumentum said it now expects fourth-quarter revenue of $465 million to $475 million, up from prior guidance of $440 million to $470 million.
The company noted that it expects to achieve $500 million of revenue in the first quarter of fiscal 2026, a quarter earlier than previously planned. 
Lumentum also raised its fourth-quarter earnings guidance from a range of 70 cents to 80 cents per share to a new range of 78 cents to 85 cents per share. The company said it anticipates a fourth-quarter operating margin of 14% to 15%, up from prior guidance of 13% to 14%.
Lumentum&#8217;s management team will discuss the updated forecast at the BofA Securities 2025 Global Technology Conference&nbsp;on Wednesday. 
See Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45759307/sportsmans-warehouse-stock-tanks-after-q1-earnings-revenues-miss-details">Sportsman&#8217;s Warehouse Stock Tanks After Q1 Earnings, Revenues Miss: Details</a>
<h1 class="wp-block-heading">How To Buy LITE Stock</h1>
Besides going to a brokerage platform to purchase a share — or fractional share — of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For Lumentum, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
LITE Price Action: Lumentum shares were up 3.67% in after-hours, trading at $80.50 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Guidance

After-Hours Center

Movers

LITE

Lumentum Stock Jumps After The Close On Rosier Outlook

Unitil Corp Files For Stock Shelf; Size Not Disclosed

Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) has outperformed the market over the past 5 years by 37.8% on an annualized basis producing an average annual return of 50.82%. Currently, Axon Enterprise has a market capitalization of $59.09 billion. 
Buying $100 In AXON: If an investor had bought $100 of AXON stock 5 years ago, it would be worth $818.05 today based on a price of $759.07 for AXON at the time of writing.
<h3>Axon Enterprise's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748985312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AXON

$100 Invested In Axon Enterprise 5 Years Ago Would Be Worth This Much Today

CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.66 by 10.61 percent. This is a 7.59 percent decrease over earnings of $0.79 per share from the same period last year. The company reported quarterly sales of $1.10 billion which missed the analyst consensus estimate of $1.11 billion by 0.59 percent. This is a 19.80 percent increase over sales of $921.04 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

CRWD

CORRECTION: CrowdStrike Holdings Q1 Adj. EPS $0.73 Beats $0.66 Estimate, Sales $1.10B Miss $1.11B Estimate

WIIM

SPWH

SPWH stock has given up its prior loss. Sportsman's Warehouse shares were trading lower after the company reported worse-than-expected Q1 financial results.

Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $0.33 by 15.15 percent. This is a 9.52 percent decrease over earnings of $0.42 per share from the same period last year. The company reported quarterly sales of $7.63 billion which beat the analyst consensus estimate of $7.50 billion by 1.69 percent. This is a 5.87 percent increase over sales of $7.20 billion the same period last year.

CORRECTION: Hewlett Packard Q2 Adj. EPS $0.38 Beats $0.33 Estimate, Sales $7.63B Beat $7.50B Estimate

HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) released its first-quarter results after Tuesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/06/g45757436/healthequity-reports-first-quarter-ended-april-30-2025-financial-results">details from the report. </a>
The Details: HealthEquity reported quarterly earnings of 97 cents per share, which beat the consensus estimate of 88 cents. Quarterly revenue came in at $330.8 million, beating the Street estimate of $321.17 million.
Read Next: <a href="https://www.benzinga.com/news/space/25/06/45724938/space-stocks-weekly-countdown-rocketlab-gets-analyst-love-while-virgin-galactic-slides-into-june?utm_source=articleShare">Space Stocks Weekly Countdown: RocketLab Gets Analyst Love While Virgin Galactic Slides Into June</a>
The company reported: 
<ul class="wp-block-list">
<li>9.9 million HSAs, an increase of 9% compared to the first quarter of FY25.</li>
<li>Total HSA Assets of $31.3 billion, an increase of 15% compared to the first quarter of FY25.</li>
<li>17.1 million Total Accounts, including both HSAs and complementary CDBs, an increase of 7% compared to first quarter FY25.</li>
</ul>
&#8220;The HealthEquity team started fiscal 2026 with a strong first quarter that included record quarterly revenue, record Adjusted EBITDA and increased guidance for the year,&#8221; said Scott Cutler, CEO of HealthEquity.
&#8220;We enhanced our member-first secure mobile experience to strengthen the security of our members&#8217; $31 billion of HSA Assets, increase member resources, and reduce costs.&#8221;
Outlook:&nbsp;HealthEquity raised its fiscal 2026 adjusted EPS guidance from a range of $3.57 to $3.74&nbsp;to&nbsp;a new range of $3.61 to $3.78, versus the&nbsp;$3.63&nbsp;analyst estimate. The company reiterated its 2026 revenue outlook for a range of&nbsp;$1.28 billion to $1.3 billion, versus the $1.3 billion estimate.
HQY Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Health Equity stock was up 5.01% at $108.96 in Tuesday's extended trading.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/social-media/25/06/45749596/the-viral-student-loan-solution-people-cant-stop-talking-about?utm_source=articleShare">The Viral Student Loan Solution People Can&#8217;t Stop Talking About</a></li>
</ul>
Image: Shutterstock

Health Care

HealthEquity Shares Trade Higher After Better-Than-Expected Q1 Report: Here's Why

Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.08) by 25 percent. This is a 40 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $56.52 million which beat the analyst consensus estimate of $55.59 million by 1.68 percent. This is a 10.12 percent increase over sales of $51.33 million the same period last year.

BASE

CORRECTION: Couchbase Q1 Adj. EPS $(0.06) Beats $(0.08) Estimate, Sales $56.52M Beat $55.59M Estimate

EPR Properties: Files For Mixed Shelf Offering; Size Not Disclosed

<h3>Gainers</h3>
<ul>
<li>Blue Hat Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHAT#NASDAQ">BHAT</a>) shares increased by 33.7% to $2.3 during Tuesday's after-market session. The market value of their outstanding shares is at $11.3 million. </li>
<li>Baosheng Media Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAOS#NASDAQ">BAOS</a>) shares rose 26.14% to $2.99. The market value of their outstanding shares is at $4.5 million. </li>
<li>BloomZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) stock moved upwards by 17.68% to $0.2. The market value of their outstanding shares is at $2.8 million. </li>
<li>CTRL Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCTR#NASDAQ">MCTR</a>) shares moved upwards by 14.74% to $37.75. The company's market cap stands at $577.5 million. </li>
<li>NFT (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MI#AMEX">MI</a>) stock rose 10.08% to $2.62. The market value of their outstanding shares is at $13.2 million. </li>
<li>ZW Data Action Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNET#NASDAQ">CNET</a>) shares moved upwards by 7.51% to $1.43. The company's market cap stands at $3.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>GD Culture Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDC#NASDAQ">GDC</a>) stock decreased by 6.0% to $2.65 during Tuesday's after-market session. The market value of their outstanding shares is at $44.5 million. </li>
<li>AirNet Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTE#NASDAQ">ANTE</a>) stock decreased by 5.34% to $0.75. The company's market cap stands at $10.7 million. </li>
<li>QMMM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMMM#NASDAQ">QMMM</a>) shares declined by 4.77% to $1.0. The company's market cap stands at $17.2 million. </li>
<li>Brag House Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBH#NASDAQ">TBH</a>) stock declined by 4.74% to $0.56. The market value of their outstanding shares is at $6.0 million. </li>
<li>NIP Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>) stock decreased by 3.9% to $1.48. The company's market cap stands at $83.2 million. </li>
<li>LQR House (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YHC#NASDAQ">YHC</a>) shares decreased by 3.82% to $1.25. The company's market cap stands at $1.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANTE

BAOS

BHAT

BLMZ

CNET

MCTR

NIPG

QMMM

12 Communication Services Stocks Moving In Tuesday's After-Market Session

Press Releases

URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer

Penny Stocks

Deadline Approaching: UroGen Pharma Ltd. (URGN) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith

Legal

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd.  - URGN

UROGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against UroGen Pharma Ltd. and Encourages Investors to Contact the Firm

Law Offices of Frank R. Cruz Encourages UroGen Pharma Ltd. (URGN) Investors To Inquire About Securities Fraud Class Action

UROGEN PHARMA LTD. (NASDAQ: URGN) INVESTOR ALERT: Investors With Large Losses in UroGen Pharma Ltd. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Rosen Law Firm Urges UroGen Pharma Ltd. (NASDAQ: URGN) Stockholders With Large Losses to Contact the Firm for Information About Their Rights

URGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Comments

UroGen Pharma

Vendite allo scoperto

UroGen Pharma (NASDAQ:URGN) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO